





Q2 FY2019 - Investor presentation 27 November 2018





THIS PRESENTATION IS NOT AN OFFER OR SOLICITATION OF AN OFFER TO BUY OR SELL SECURITIES IN THE UNITED STATES OF AMERICA OR IN ANY OTHER JURISDICTION. IT IS PROVIDED AS INFORMATION ONLY

This presentation is furnished only for the use of the intended recipient, and may not be relied upon for the purposes of entering into any transaction. By attending this presentation, you agree to be bound by these restrictions. Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

Certain information herein (including market data and statistical information) has been obtained from various sources. We do not represent that it is complete or accurate. All projections, valuations and statistical analyses are provided to assist the recipient in the evaluation of the matters described herein. They may be based on subjective assessments and assumptions and may use one among alternative methodologies that produce different results and to the extent that they are based on historical information, they should not be relied upon as an accurate prediction of future performance.

This presentation may include forward-looking statements that reflect our intentions, beliefs or current expectations. Forward-looking statements involve all matters that are not historical by using the words "may", "will", "would", "expect", "intend", "estimate", "anticipate", "believe", and similar expressions or their negatives. Such statements are made on the basis of assumptions and expectations that we currently believe are reasonable, but could prove to be wrong.

This presentation does not constitute an offer or an agreement, or a solicitation of an offer or an agreement, to enter into any transaction (including for the provision of any services) and does not constitute an offer or invitation to subscribe for or purchase any securities, and nothing contained herein shall form the basis of any contract or commitment whatsoever. Any decision to purchase securities in the context of a proposed offering, if any, should be made solely on the basis of information contained in the offering memorandum published in relation to such an offering.

The information contained herein does not constitute investment, legal, accounting, regulatory, taxation or other advice and the information does not take into account your investment objectives or legal, accounting, regulatory, taxation or financial situation or particular needs. You are solely responsible for forming your own opinions and conclusions on such matters and the market and for making your own independent assessment of the information herein. You are solely responsible for seeking independent professional advice in relation to the information and any action taken on the basis of the information. Investors and prospective investors in the securities of any issuer mentioned herein are required to make their own independent investigation and appraisal of the business and financial condition of such issuer and the nature of the securities.

This presentation includes certain financial data that are "non-IFRS financial measures". These non-IFRS financial measures do not have a standardised meaning prescribed by International Financial Reporting Standards or UK Accounting Standards and therefore may not be directly comparable to similarly titled measures presented by other entities, nor should they be construed as an alternative to other financial measures determined in accordance with International Financial Reporting Standards or UK Accounting Standards. Although we believe these non-IFRS financial measures provide useful information to users in measuring the financial performance and condition, of the business, you are cautioned not to place undue reliance on any non-IFRS financial measures included in this presentation. This presentation contains certain data and forward looking statements regarding the UK economy, the markets in which we operate and its position in the industry that were obtained from publicly available information, independent industry publications and other third party data. We have not independently verified such data and forward looking statements and cannot guarantee their accuracy or completeness.

Agenda

{idh} group

- Introduction
- Performance & business update
 - mydentist developments
 - Dental Directory developments
- Financial review
- Outlook
- Q&A


Introduction



- The group remains in a turnaround phase
- New leadership is embedded and working well
- Encouraging early signs of improvement in both mydentist and now,
 Dental Directory
- Pick up in mydentist NHS revenue is taking longer than expected
- Strong support from clinicians to accelerate growth in private revenue
- Discipline and initiatives regarding cost control supporting EBITDA progression
- Remain on track for full year guidance



Q2 FY2019
Performance & business update



Q2 FY2019 group performance





Group

- Revenue down 0.4% in H1 and down 2.2% YoY to £139.3m for the quarter
- Gross profit down 1.1% YoY to £62.1m for the quarter
- Q2 EBITDA up £0.1m on FY2018 to £13.6m. EBITDA YTD up £0.2m on FY2018.



mydentist

- Private revenue LFL growth of 5.2% per working day for H1 (Q2: 4.7%)
- NHS revenue, excluding disposal sites, down £2.4m compared to Q2 FY2018
- EBITDA up £2.5m (11.5%) year-on-year for H1 (Q2: £0.9m)



Dental Directory

- Revenue flat YoY at £33.2m (before intergroup eliminations) for the quarter
- EBITDA up £0.8m from Q1 at £1.3m but still behind Q2 last year.



NHS revenue

- NHS revenue, excluding closed, disposal and held for sale sites, is down £2.4m compared to Q2 FY18
- Like-for-like NHS revenue per working day is down 0.4% YTD (Q2: down 1.8%)
- Like-for-like UDA delivery per working day was down 2.3% for H1 (Q2: down 3.3%)
- Operational productivity measures continue to be encouraging diary utilisation is up, Did Not Attend appointments are down and clinician contract delivery per hour is up
- However, increases still required in chair occupancy and diary hours



Private revenue

- Year-to-date like-for-like private growth per working day is 5.2%
- Q2 like-for-like private growth, adjusted for the number of working days, increased to 4.7%.
- Growth continues to be strong in hygiene (+12.2% LFL)
- The roll-out of our first 8 Advanced Oral Healthcare Centres providing specialist services such as implants and endodontics continues to provide encouraging early results
- Opportunities for further growth identified



Strategic partnership with leading oral health providers

- Proud to announce a new three year strategic partnership with Philips and GSK to provide a range of oral health products in practice
- Live from 1 October 2018







- Partnership covers a wide range of products from Sonicare toothbrushes to Sensodyne, Pronamel, Corsodyl and Aquafresh pastes, floss and mouthwash
- Also offering Philips Zoom in-surgery and take-home whitening kits
- Continue to work with TePe for interdental brushes.
- Industry-leading partnership based on feedback from clinicians, hygienists and therapists to suit patient needs



Clinical conference & dentist engagement

- In September we held our fourth mydentist Clinical Conference
- Over 650 delegates from our clinical, leadership, and key support teams
- Opportunity for management to engage with large numbers of clinicians and discuss trends in the industry







Clinician engagement

- Expanded scope to carry out an external survey to identify market trends
- mydentist trends are consistent with national market trends
- More than 80% of clinicians were keen to increase the private work undertaken particularly as they gain experience
- Survey identified that clinicians were willing to increase hours and flexibility of hours to increase private treatment opportunities
- Clinicians keen to spend more time with each patient
- Patients are progressively paying more for dentistry costs as the NHS patient charge increases
- Market gap emerging between NHS and high cost private treatments
- Existing "Access mydentist" programme being used to pilot options



Resourcing & on-boarding

- Resourcing remains a key priority for the business
- Continuing to build up the pipeline of new dentists
- Looking at options to bring in clinicians to develop affordable private options rather than wait for NHS performer numbers
- Make on-boarding as efficient and rapid as possible
- Additional net 38 clinicians started in practice during the quarter
- Increase in leavers as performance management improves of dentists not delivering NHS targets or appropriate clinical standards
- Catch-up in net Q1 clinicians due to late reporting of leavers within operational systems
- YTD net 52 clinicians started in practice



Awards

- Practices, clinicians and support teams shortlisted for 27 awards across 5 different award ceremonies
- Scottish Dentistry Awards
 - Clinical Director: "Most Invaluable Team Member"
- Oral Health Awards
 - Hygienist of the Year
 - Best Leader in Prevention
- Dental Industry Awards
 - Best Website
 - Best Dental brand
 - Best Service & Repair Company: Dental Directory/Mi-Tec

Q2 FY2019 summary – **Dental Directory**



- Paul Adams, the new MD, has moved quickly to improve performance from Q1
- Total revenue, excluding sales to mydentist, up 2.6% to £26.1m from £25.5m in Q2 FY2018
- Like-for-like revenue down 2.0% YTD with shortfalls in High Street sales partially offset by growth in equipment
- Gross margin down from 27.6% to 26.8%, but up 1.0% on Q1
- Cost reduction in overheads is progressing with streamlining of management complete at the end of Q2
- Improvements in customer service from call handling to delivery
- Further opportunities identified to improve run rate through Q3 and Q4



Financial review



Q2 FY2019 Financial highlights



- Group revenue down 0.4% YTD (Q2: down 2.2% to £139.3m)
- LFL mydentist private revenue up 5.2% per working day for the year (Q2: up 4.7%)
- Private revenue increasing proportion of dental practice revenue

Dental practice revenue	Q2 FY2019	Q2 FY2018
NHS	77.2%	78.4%
Private	22.8%	21.6%

- As expected EBITDA in line with Q2 FY2018 and with guidance
- mydentist EBITDA up £0.9m offset by Dental Directory down £0.8m
- LTM EBITDA of £55.3m and pro-forma adjusted EBITDA of £57.3m
- No difference in trading days in Q2 (64 days) YTD FY2019 126;
 FY2018 125)

Financial results for Q2 FY2019 Income statement



	Q2 FY2019 £m	% of revenue	Q2 FY2018* £m	% of revenue	% change
Revenue	139.3		142.4		(2.2)%
Gross profit	62.1	44.6%	62.8	44.1%	(1.1)%
Overheads**	(48.9)	35.1%	(49.8)	35.0%	1.7%
Other operating income	0.5	0.3%	0.5	0.4%	(7.4)%
EBITDA	13.6	9.8%	13.5	9.5%	0.8%


^{*} Restated for implementation of IFRS 15 – Revenue from contracts with customers

^{**} Administrative expenses plus distribution costs before depreciation, amortisation, impairment and other non-underlying items

Financial results for Q2 FY2019


Group revenue bridge





Financial results for Q2 FY2019Group EBITDA bridge





Financial results for Q2 FY2019

Acquisitions & Disposals



- Total of 625 practices at 30 September 2018 (661 at 30 September 2017)
- The actions from the portfolio review during the quarter led to:
 - Closure of 4 practices in Q2 (YTD 9 practices)
 - Sale of 6 practices (YTD 9 practices)
 - 19 practices now classified as held for sale on the balance sheet
- Remaining practices will mainly be sold or closed during Q3
- Delays due to constraints placed on contract transfers by the NHS
- No plans for any further acquisitions in either division
- PDS Dental Laboratory sold in October
- Early results from the orthodontic tenders have led to some reductions in contract size as smaller overall lots have been allocated

Financial results for Q2 FY2019 Cash flow statement



£m	Q2 FY2019	Q2 FY2018
Cash generated from operations	16.6	21.5
Net capital expenditure*	(5.9)	(3.5)
Corporation tax	-	-
Cash flow before acquisitions and debt service	10.7	18.0
Interest	(14.4)	(14.2)
Cash flow before acquisitions and financing	(3.7)	3.8
Acquisitions**	(0.1)	(1.5)
Debt issue costs	-	-
Financing	-	-
Net cash flow	(3.8)	2.3
Opening cash	15.1	12.8
Closing cash	11.3	15.1
Net debt	537.6	526.3

^{*} Net capital expenditure includes £0.4m proceeds from the sale of practices (Q2 FY2018 includes £0.3m from disposals)

^{**} Excluding fees







Q3 FY2019 Outlook



- H1 has seen Dental Directory down on last year offset by some encouraging signs in mydentist; overall results in line with expectations
- mydentist:
 - EBITDA growth in H1 of 11.5% and improvement in EBITDA margin of 1.2%
 - Improvement driven by tighter cost control
 - Q3 expected to benefit from a further increase in UDA rates (+1.34% from October) and continued cost control
- Dental Directory
 - Turnaround in gross margin with new leadership
 - Significant overhead savings underway
 - EBITDA will be down on prior year but improving in H2
- Group EBITDA for Q3 FY2019 likely to be up on prior year by c£1m at £15.0m-£15.8m (FY18 restated: £14.7m)

FY2019 Outlook - no change



- Expect to see growth year-on-year in H2 in mydentist
- mydentist EBITDA forecast at £53m-£55m
- Dental Directory forecast at c£5m
- Outturn for the year unchanged between £58m-£60m
- Capex investment in practices increase of £3m-£4m over the year
- Cash outflow likely in H2 small drawdown from the SSRCF
- Continue to keep acquisitions on hold until confident of sustained turnaround in performance

Summary



- Encouraging progress in mydentist but EBITDA growth coming from cost control rather than revenue improvements
 - Overall NHS revenue in line with prior year per working day for the year
 - Private revenue growth over 5% per working day YTD
 - EBITDA up by £2.5m over H1 FY2018
 - Continued forward momentum depends on the ability to increase overall productive capacity
- New management in Dental Directory have now started to make progress
 - Expect turnaround to accelerate in Q3
 - Strong focus on margin and cost control continues





Contact details:

Further questions can be addressed to:

- Email: investorrelations@mydentist.co.uk

- Telephone: 01204 799651

Investor information is available from our dedicated investor website:

www.mydentist.co.uk/about-us/investors

